Questions? +1 (202) 335-3939

Trusted News Since 1995

A service for global professionals · Saturday, May 3, 2025 · 809,145,730 Articles · 3+ Million Readers

News Search | All News Topics > ISO News Topics: By Country | By State

Search Tips

Here you can find useful examples and description about searching the news archive. Read it carefully to get the best results. If you need more help, please contact us.

Quick Overview

Searching is case insensitive. Words music and mUSIC return the same results.
Some of the common words like the, is, etc. are not included in your search.

Search Term Syntax

The symbol "|" stands for OR and symbol "&" stands for AND.

Term	Description
\|	Using \| operator gives you articles for every keyword in the search term.
&	Using & operator gives you only those articles that contain all keywords in the string.
" " (quotation marks)	Using quotation marks limits your search for exact phrases.
* (asterisk sign)	Using an asterisk sign gives you variations of aroot keyword. You cannot use it in phrases.
(parenthesis)	You can use parenthesis to adjust the priority of your search phrase evaluation (as common math/boolean expressions).

Examples

Keywords (search phrase)	Description
music	will search for any articles that contain the word music
music \| band \| song	will search for articles containing any of the keywords
nhl & hockey	will search for articles containing both words. (Note: & can be omitted in this case)
"white house" \| senate	will search for articles containing the phrase white house or the word senate
"flower show" & tulip	will search for articles containing both the phrase flower show and the word tulip
bank*	will search for articles containing bank, banks, banking, banker etc. Using * (asterisk sign) gives you variations of the root keyword.
student* & ( protest* \| demonstrat* )	will search for articles containing the words student or students, etc. in combinations with protest, protests, demonstrate, demonstration, etc.

Need more help? Contact us at our helpdesk.

Published on Apr 30, 2025

AstraZeneca’s Calquence regimens recommended by CHMP for chronic lymphocytic leukaemia

AstraZeneca (AZ) has announced that its Calquence (acalabrutinib) regimens have been recommended by the European Medicines Agency’s human medicines committee to treat chronic lymphocytic leukaemia (CLL). The Committee for Medicinal Products for Human Use ( …

Source: PMLiVE - Neutral
Published on Apr 30, 2025

AstraZeneca to scrap trails of Truqap in prostate cancer after interim analysis

Cambridge: UK-pharma major AstraZeneca has announced plans of discontinuing the Phase III trial of its oncology asset Truqap (capivasertib) in prostate cancer, following an interim analysis suggesting that the “drug is unlikely to meet the dual primary …

Source: ETPharma.com - Pending
Published on Apr 30, 2025

AstraZeneca’s Truqap fails in another Phase III trial

AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely to meet its endpoints. The CAPItello-280 study (NCT05348577) was investigating Truqap in combination with docetaxel and androgen- …

Source: Clinical Trials Arena - Pending
Published on Apr 29, 2025

Drugmaker AstraZeneca shifts more production to US amid Trump tariffs

AstraZeneca said it was shifting the production of some medicines sold in the United States from Europe to the US, to counter the impact of Donald Trump’s trade tariffs. Speaking as the company reported higher sales and profits for the first quarter, the …

Source: The Guardian - Center-left
Published on Apr 30, 2025

EMA committee recommends approval of AstraZeneca's fixed─duration Calquence─based regimens for 1st─line chronic ...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously untreated …

Source: Pharmabiz.com - Neutral
Published on Apr 30, 2025

AstraZeneca discontinues Phase 3 trial of Truqap in metastatic castration-resistant prostate cancer

AstraZeneca has announced the discontinuation of the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo …

Source: Medical Dialogues - Indeterminate
Published on Apr 30, 2025

AstraZeneca to discontinue CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer

AstraZeneca is discontinuing the CAPItello-280 phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared to docetaxel and ADT with placebo in patients with …

Source: Pharmabiz.com - Neutral
Published on Apr 30, 2025

AstraZeneca Partners with Revna Biosciences to Enhance Epidermal Growth Factor Receptor (EGFR) ...

AstraZeneca, a global biopharmaceutical company is in collaboration with Revna Biosciences (www.RevnaBio.com), a precision medicine research and advanced diagnostics company to provide EGFR (Epidermal Growth Factor Receptor) biomarker testing in Ghana. …

Source: Business Ghana - Pending
Published on Apr 29, 2025

AstraZeneca ‘committed’ to US manufacturing as profits rise

Source: The Financial Times - Neutral
Published on Apr 30, 2025

The United States is a key market for the pharmaceutical industry, and AstraZeneca had already planning to invest $3.5 ...

Source: Barron News Shield - Wisconsin - Neutral